AMAG Pharma (AMAG) Misses Q1 EPS by 17c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
May 3, 2016 7:01 AM EDTFirst quarter 2016 non-GAAP product revenue increased 52% to $117.6 million1Entered into new Makena® partnership with a leading provider of home nursing services
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Â AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today reported unaudited consolidated financial results for the first quarter ended March 31, 2016.
Most notably, the first quarter of 2016 included... More
